| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Blood | 2009 | 3.2K |
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Cancer Cell | 2005 | 2.4K |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 2.3K |
| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 2.3K |
| International uniform response criteria for multiple myeloma | Leukemia | 2006 | 2K |
| Improved survival in multiple myeloma and the impact of novel therapies | Blood | 2008 | 1.8K |
| Review of 1027 patients with newly diagnosed multiple myeloma | Mayo Clinic Proceedings | 2003 | 1.5K |
| Changes in Burnout and Satisfaction With Work-Life Balance in Physicians and the General US Working Population Between 2011 and 2014 | Mayo Clinic Proceedings | 2015 | 1.4K |
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | British Journal of Haematology | 1998 | 1.2K |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1.2K |
| Multiple myeloma | New England Journal of Medicine | 2004 | 1.2K |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1.2K |
| A long-term study of prognosis in monoclonal gammopathy of undetermined significance | New England Journal of Medicine | 2002 | 1.1K |
| Calcineurin: form and function | Physiological Reviews | 2000 | 1.1K |
| Chimeric antigen receptor T-cell therapy - assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1.1K |
| Burnout and medical errors among American surgeons | Annals of Surgery | 2010 | 1.1K |
| Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma | Journal of Clinical Oncology | 2006 | 1K |
| Interventions to prevent and reduce physician burnout: a systematic review and meta-analysis | Lancet, The | 2016 | 999 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma | New England Journal of Medicine | 2015 | 928 |
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 | Journal of the National Cancer Institute | 2005 | 918 |
| Prevalence of monoclonal gammopathy of undetermined significance | New England Journal of Medicine | 2006 | 902 |
| Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor | Journal of Thrombosis and Haemostasis | 2006 | 884 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients | Leukemia | 2014 | 880 |
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Blood | 2006 | 833 |
| Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | Lancet Oncology, The | 2015 | 832 |
